2020 American Transplant Congress
Efficacy and Safety of Single-Dose Rabbit Anti-Thymocyte Globulin versus Basiliximab Induction among Pediatric Kidney Transplant Recipients
Hospital do Rim, Sao Paulo, Brazil
*Purpose: Induction therapy is a standard component of kidney transplant immunosuppression protocols. However, in the pediatric population, there are still uncertainties about the ideal induction…2020 American Transplant Congress
Safety and Efficacy of Low Dose Rabbit Antithymocyte Globulin in Pediatric Renal Transplant Recipients
*Purpose: Currently there is no consensus among pediatric kidney transplant centers regarding the use and regimen for immunosuppressive induction therapy.The safety and effectiveness of reduced…2020 American Transplant Congress
Single-Dose Anti-Thymocyte Globulin is Non-Inferior to Divided-Dose for Induction Therapy in Kidney and Pancreas Transplantation
*Purpose: Emerging studies suggest that single-dose rabbit antithymocyte globulin (rATG) is not inferior to the divided-dose, however this dosing strategy has never been evaluated in…2020 American Transplant Congress
Adult Primary Liver Transplant Recipient Outcomes by Immunosuppression Induction Received
*Purpose: It has long been recognized that the highest risk of rejection of an organ is in the first few months post transplantation. To prevent…2020 American Transplant Congress
Basiliximab Induction in the Obese: One Size Does Fit All
*Purpose: Surgical advancements allow more obese (BMI> 30 kg/m2) patients to receive a renal transplant. The original clinical and pharmacokinetic (PK) trials in transplantation immunosuppression…2020 American Transplant Congress
The FcγRIIIa-158 VV Genotype Increased the Risk of Post-Transplant Lymphoproliferative Disorder in T-Cell Depleted Kidney Transplant Recipients
1CHU Tours, Tours, France, 2CHU Limoges, Limoges, France
*Purpose: Post-transplantation lymphoproliferative disorder (PTLD) is a severe complication in organ transplant recipients. The use of T lymphocyte-depleting antibodies (TLDAb), especially rabbit TLDAb contributes to…2020 American Transplant Congress
Induction Immunosuppression with Thymoglobulin May Improve Graft Outcomes without Increasing a Risk for Infection in Patients Undergoing Liver Transplantation Alone
*Purpose: Immunosuppression protocols for liver transplant (LT) vary between institutions and roles of induction immunosuppression in LT remain controversial. The aim of this study was…2020 American Transplant Congress
The Challenge of Selecting an Induction Agent: A Dual Regimen for Medically High-Risk Kidney Recipients
Weill Cornell Medical Center, New York, NY
*Purpose: Complications of the commonly used lymphocyte-depleting induction agent, rabbit anti-thymocyte globulin (rATG),include cardiorespiratory dysfunction with hypotension, tachycardia, myocardial infarction, and pulmonary edema. The choice…2019 American Transplant Congress
A Randomized Controlled Clinical Trial of Thymoglobulin® and Extended Delay of Calcineurin Inhibitor Therapy for Renal Protection after Liver Transplantation: A Multicenter Study
*Purpose: Thymoglobulin® (r-ATG) has been used as induction therapy in liver transplantation (LT). No prospective, randomized, controlled, trial (RCT) has been performed to evaluate effect…2019 American Transplant Congress
Alemtuzumab versus Anti-Thymocyte Globulin Induction in the Setting of Immediate Post-Renal Transplant Acute Tubular Necrosis in an Urban, Minority Patient Population
University of Illinois at Chicago, Chicago, IL
*Purpose: Post-renal transplant (RTx) delayed graft function (DGF) or slow graft function (SGF) increase the risk of rejection and impair allograft function. Lymphocyte depleting induction…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 31
- Next Page »